Search This Blog

Tuesday, January 12, 2021

Codagenix, Serum Institute Start Phase 1 Trial of COVI-VAC Single Dose Intranasal Covid Vax

 - Randomized, double-blind, placebo-controlled, dose-escalation trial

- 48 volunteers to be evaluated at three dose levels

- Endpoints include safety, tolerability and immunogenicity

- Initial data expected by mid-2021

https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-dosing-in-phase-1-trial-of-covi-vac-a-single-dose-intranasal-live-attenuated-vaccine-for-covid-19-301203130.html

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)